Combined exosome of adipose-derived mesenchymal stem cell and hyaluronic acid delays early osteoarthritis progression of ovine sheep model: Clinical, radiographic, macroscopic and microscopic evaluation.

Q2 Pharmacology, Toxicology and Pharmaceutics

F1000Research Pub Date : 2025-02-13 eCollection Date: 2024-01-01 DOI:10.12688/f1000research.147309.2

Ludwig Andribert Powantia Pontoh, Jessica Fiolin, Ismail Hadisoebroto Dilogo, Marcel Prasetyo, Radiana Dhewayani Antarianto, Alida Harahap, Angela Jennifer Tantry, Trevino Aristakus Pakasi, Bambang Pontjo Priosoeryanto, Tri Isyani Tungga Dewi

{"title":"Combined exosome of adipose-derived mesenchymal stem cell and hyaluronic acid delays early osteoarthritis progression of ovine sheep model: Clinical, radiographic, macroscopic and microscopic evaluation.","authors":"Ludwig Andribert Powantia Pontoh, Jessica Fiolin, Ismail Hadisoebroto Dilogo, Marcel Prasetyo, Radiana Dhewayani Antarianto, Alida Harahap, Angela Jennifer Tantry, Trevino Aristakus Pakasi, Bambang Pontjo Priosoeryanto, Tri Isyani Tungga Dewi","doi":"10.12688/f1000research.147309.2","DOIUrl":null,"url":null,"abstract":"Background: Current treatment of osteoarthritis (OA) mainly focused on treating symptoms. Exosome from Adipose-derived Mesenchymal Stem Cell (Ad-MSC) have been shown to delay degenerative process. This study aimed to investigate the clinical, radiological and histological impact of combined intra-articular (IA) hyaluronic acid (HA) and exosome Ad-MSCs in-vivo using a larger animal model with low-grade OA.Methods: Eighteen male Ovies aries sheep underwent total lateral meniscectomy and conventional radiography was performed to confirm low-grade OA after 6 weeks. The sheep were divided into three groups, Group 1 (G1; n=6) received thrice exosome injections, G2 (n=6) received twice HA injection, and G3 (n=6) received both treatments with a 1-week interval after 10 days of meniscectomy. Clinical evaluations were conducted using the Clinical Lameness Score (CLS), radiographic with X-ray using OA score by Innes et al, while macroscopic evaluation by Osteoarthritis Research Society International (OARSI) scores.Results: Lameness parameter scored lowest in G3 significantly (2.0±0.0 VS 2.7±0.52 VS 2.7±0.52; p=0.024) at the second month although the overall CLS score did not significantly differ at the 3 rd month. The best improvement of conventional total OA radiographic score at the 3 rd month compared to all groups (5.2±1.17 vs 6.3±0.82 vs 6.7±1.03; p=0.053). Macroscopic OARSI evaluation showed no difference (p=0.711).Conclusions: Combined repeated exosome Ad-MSC and HA IA injection proven to delay OA progression, however longer duration of follow up is required to evaluate its long-term effect.","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":"13 ","pages":"494"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842963/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.147309.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Current treatment of osteoarthritis (OA) mainly focused on treating symptoms. Exosome from Adipose-derived Mesenchymal Stem Cell (Ad-MSC) have been shown to delay degenerative process. This study aimed to investigate the clinical, radiological and histological impact of combined intra-articular (IA) hyaluronic acid (HA) and exosome Ad-MSCs in-vivo using a larger animal model with low-grade OA.

Methods: Eighteen male Ovies aries sheep underwent total lateral meniscectomy and conventional radiography was performed to confirm low-grade OA after 6 weeks. The sheep were divided into three groups, Group 1 (G1; n=6) received thrice exosome injections, G2 (n=6) received twice HA injection, and G3 (n=6) received both treatments with a 1-week interval after 10 days of meniscectomy. Clinical evaluations were conducted using the Clinical Lameness Score (CLS), radiographic with X-ray using OA score by Innes et al, while macroscopic evaluation by Osteoarthritis Research Society International (OARSI) scores.

Results: Lameness parameter scored lowest in G3 significantly (2.0±0.0 VS 2.7±0.52 VS 2.7±0.52; p=0.024) at the second month although the overall CLS score did not significantly differ at the 3 ^rd month. The best improvement of conventional total OA radiographic score at the 3 ^rd month compared to all groups (5.2±1.17 vs 6.3±0.82 vs 6.7±1.03; p=0.053). Macroscopic OARSI evaluation showed no difference (p=0.711).

Conclusions: Combined repeated exosome Ad-MSC and HA IA injection proven to delay OA progression, however longer duration of follow up is required to evaluate its long-term effect.

查看原文本刊更多论文

背景：目前对骨关节炎（OA）的治疗主要集中在治疗症状上。脂肪间充质干细胞（Ad-MSC）的外泌体已被证明可延缓退行性过程。本研究旨在利用一个较大的低级OA动物模型，研究关节内透明质酸（HA）和Ad-间充质干细胞外泌体在体内联合应用对临床、放射学和组织学的影响：18只雄性Ovies aries绵羊接受了全外侧半月板切除术，并在6周后进行了常规X光检查以确认低级别OA。绵羊分为三组，第一组（G1；n=6）接受三次外泌体注射，第二组（n=6）接受两次 HA 注射，第三组（n=6）在半月板切除 10 天后接受两种治疗，间隔 1 周。临床评估采用临床跛行评分（CLS），X光检查采用Innes等人的OA评分，宏观评估采用国际骨关节炎研究学会（OARSI）评分：G3的跛行参数在第二个月得分最低（2.0±0.0 VS 2.7±0.52 VS 2.7±0.52；P=0.024），尽管CLS总分在第3个月没有显著差异。第 3 个月时，常规 OA 总放射学评分与所有组相比改善最好（5.2±1.17 vs 6.3±0.82 vs 6.7±1.03；P=0.053）。宏观OARSI评估显示无差异（p=0.711）：结论：重复注射外泌体Ad-MSC和HA IA可延缓OA进展，但需要更长时间的随访来评估其长期效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

F1000Research Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

5.00

自引率

0.00%

发文量

1646

审稿时长

1 weeks

期刊介绍： F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.